Inhaled Nitric Oxide Phase 2 Trial Investigates Acute Severe Right Heart Failure in PH

Acute right heart failure (RHF) in patients with pulmonary hypertension (PH) is a life-threatening condition. Pulmonary arterial hypertension (PAH), a severe form of PH, is characterized by progressive increases in pulmonary vascular resistance, leading to right ventricular failure and systemic inflammation. Current treatments often fall short in rapidly addressing acute decompensation, leaving a significant gap for interventions that can quickly reduce pulmonary vascular resistance and improve right ventricular function. Inhaled nitric oxide (iNO) is a rapid pulmonary vasodilator, making it a promising candidate for acute severe RHF.

This was a Phase 2, Randomized, Clinical Trial (the PHiNO Study) designed to investigate the efficacy and safety of inhaled nitric oxide (iNO; INOflo® for inhalation 800 ppm). The study enrolled patients experiencing acute severe right heart failure due to pulmonary hypertension. The primary objective was to assess the therapeutic potential of iNO as a rapid pulmonary vasodilator in this critical patient population. Specific details regarding patient numbers, duration of treatment, or primary endpoints were not provided in the abstract.

The provided abstract describes the design and rationale for the PHiNO study, a Phase 2 clinical trial. It outlines the investigation into the efficacy and safety of inhaled nitric oxide for acute severe right heart failure with pulmonary hypertension. However, the abstract does not report any specific results, data, or findings from the trial itself. Therefore, no outcomes, statistical significances, or quantitative measures of efficacy or safety can be presented at this time. The study's objective is to determine these outcomes.